

Synthesis, Radiolabeling, and Preliminary in vivo Evaluation of [⁶⁸Ga] IPCAT-NOTA as an Imaging Agent for Dopamine Transporter

Shiou-Shiow Farn ^{1,2}
Kang-Wei Chang³
Wan-Chi Lin¹
Hung-Man Yu ¹
Kun-Liang Lin¹
Yu-Chin Tseng¹
Yu Chang¹
Chung-Shan Yu^{2,4}
Wuu-Jyh Lin¹

¹Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, 32546, Taiwan; ²Department of Biomedical Engineering and Environmental Sciences, National Tsing-Hua University, Hsinchu, 300, Taiwan; ³Laboratory Animal Center, Office of Research and Development, Taipei Medical University, Taipei, 11031, Taiwan; ⁴Institute of Nuclear Engineering and Science, College of Nuclear Science, National Tsing-Hua University, Hsinchu, 300, Taiwan

Introduction: Novel radiotracer development for imaging dopamine transporters is a subject of interest because although [^{99m}Tc]TRODAT-1, [¹²³I]β-CIT, and [¹²³I]FP-CIT are commercially available; ⁹⁹Mo/^{99m}Tc generator is in short supply and ¹²³I production is highly dependent on compact cyclotron. Therefore, we designed a novel positron emission tomography (PET) tracer based on a tropane derivative through C-2 modification to conjugate NOTA for chelating ⁶⁸Ga, a radioisotope derived from a ⁶⁸Ge/⁶⁸Ga generator.

Methods: IPCAT-NOTA **22** was synthesized and labeled with [⁶⁸Ga]GaCl₄⁻ at room temperature. Biological studies on serum stability, LogP, and in vitro autoradiography (binding assay and competitive assay) were performed. Furthermore, ex vivo autoradiography, biodistribution, and dynamic PET imaging studies were performed in Sprague Dawley rats.

Results: [⁶⁸Ga]IPCAT-NOTA **24** obtained had a radiochemical yield of ≥90% and a specific activity of 4.25 MBq/nmol. [⁶⁸Ga]IPCAT-NOTA **24** of 85% radiochemical purity (RCP%) was stable at 37°C for up to 60 minutes in serum with a lipophilicity of 0.88. The specific binding ratio (SBR%) reached 15.8 ± 6.7 at 60 minutes, and the 85% specific uptake could be blocked through co-injection at 100- and 1000-fold of the cold precursor in in vitro binding studies. Tissue regional distribution studies in rats with [⁶⁸Ga]IPCAT-NOTA **24** showed striatal uptake (0.02% at 5 minutes and 0.007% at 60 minutes) with SBR% of 6%, 25%, and 62% at 5–15, 30–40, and 60–70 minutes, respectively, in NanoPET studies. The RCP% of [⁶⁸Ga]IPCAT-NOTA **24** at 30 minutes in vivo remained 67.65%.

Conclusion: Data described here provide new information on the design of PET probe of conjugate/pendent approach for DAT imaging. Another chelator or another direct method of intracranial injection must be used to prove the relation between [⁶⁸Ga]IPCAT-NOTA **24** uptake and transporter localization.

Keywords: Parkinson disease, dopamine transporter, Ga-68

Introduction

Dopamine transporter (DAT), a protein complex located in presynaptic dopaminergic nerve terminals, serves as the primary means for removing dopamine from the synaptic cleft.^{1,2} DAT provides an excellent neurochemical marker for the density and structural integrity of the dopaminergic system in inactivating and recycling dopamine.¹ The regional brain distribution of DATs was largely concentrated in the striatum, with much lower levels in the amygdala, hippocampus, substantia nigra, and ventral tegmental area.^{2,3} Therefore, measuring the decrease in DAT may be a useful indicator of dopamine neuronal loss.⁴

Correspondence: Wu-Jyh Lin;
Chung-Shan Yu
Email WJLin@seecurellc.com; csyu@mx.nthu.edu.tw



Most DAT imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT) are based on tropane derivatives,⁵ such as [¹¹C]CFT, [¹¹C]WIN-35428, [¹⁸F]FE-PE2I, [¹²³I]β-CIT, [¹²³I]FP-CIT, [¹²³I]Altoprane, and [^{99m}Tc]TRODAT-1. Of these, [^{99m}Tc]TRODAT-1, [¹²³I]β-CIT, and [¹²³I]FP-CIT were commercialized for clinical application.⁶ However, the disadvantage of [¹²³I]β-CIT is its lack of specificity, and adequate imaging should be performed 20–30 hours after injection. [^{99m}Tc]TRODAT-1, one of the conjugate/pendent approaches for cocaine-based SPECT imaging agents through N-8 or C-2 modification, was first published by Prof. Kung at the University of Pennsylvania, USA.^{6–10} [^{99m}Tc]TRODAT-1, which is technetium based, is relatively inexpensive and available in kit form. However, its specific signal is lower than that of ¹²³I-based SPECT tracers.¹¹

In recent years, ⁶⁸Ga has become a superior PET radionuclide due to increased photon flux per unit of radiation dose delivered to a patient and broad clinical usage.^{12,13} It has the following advantages: (a) a short 68-minute physical half-life with 89% β⁺ emission; (b) an alternative to well-established radiopharmaceuticals based on ^{99m}Tc, ¹¹¹In, ^{123/124}I, ¹⁸F, and ¹¹C; (c) less expensive compared with ¹²³I; and (d) high detection sensitivity and resolution, fast data acquisition, dynamic scanning, and low radiation effective dose.¹³

Several ⁶⁸Ga-labeled imaging agents have been clinically applied, particularly in oncology, such as [⁶⁸Ga]DOTANOC, [⁶⁸Ga]DOTATOC, [⁶⁸Ga]DOTATATE, and [⁶⁸Ga]HA-DOTATATE for imaging somatostatin receptors,¹⁴ [⁶⁸Ga]DOTA-PSMA-617 for imaging prostate-specific membrane antigen,¹⁵ and [⁶⁸Ga]DOTA-Pentax for imaging chemokine receptor CXCR4 based on DOTA as chelator. However, for brain research, only one report of [⁶⁸Ga]TC3-OGDOTA for Alzheimer disease imaging was published.¹⁶ Another chelator, NOTA (1,4,7-triazacyclononane-N,N',N''-triacetic acid), and its derivatives are promising stable chelators for ⁶⁸Ga for targeting proteins and peptides.¹⁷

To date, although [^{99m}Tc]TRODAT-1, [¹²³I]β-CIT, and [¹²³I]FP-CIT are commercially supplied, novel radiotracer development for imaging dopamine transporters is still a subject of interest because of the shortage in the supply of ⁹⁹Mo/^{99m}Tc generator and high dependence on compact cyclotron for [¹²³I] production. Therefore, we designed a novel PET tracer based on tropane derivative through C-2 modification to conjugate NOTA for chelating ⁶⁸Ga, a radioisotope derived from a ⁶⁸Ge/⁶⁸Ga generator.

Materials and Methods

Chemistry

Reagents used in the syntheses were purchased from Sigma-Aldrich (Sweden), MACRON (USA), J.T.Baker (USA) or Alfa Aesar (USA) and used without further purification unless otherwise indicated. Anhydrous Na₂SO₄ was used as a drying agent. ⁶⁸GaCl₃ was obtained from a ⁶⁸Ge/⁶⁸Ga generator (IGG100, Eckert & Ziegler, Berlin, Germany) and eluted with 0.1 N ultrapure HCl (J.T. Baker, Center Valley, PA, USA). Reaction yields are reported without attempts at optimization. Melting points were determined in open capillary tubes with a Buchi apparatus and are uncorrected. IR spectra were obtained on a Perkin-Elmer 283 spectrophotometer (KBr pellets for solid or nujol for liquid). ¹H NMR spectra were determined on a Varian 390 or Bruker 300 MHz instrument. Chemical shifts are given in δ values downfield from Me₄Si as an internal standard. Mass spectra were recorded on a Hewlett-Packard 5995c GC-MS low-resolution spectrometer. All compounds showed appropriate IR, ¹H NMR, and mass spectra. Elemental analyses were performed on a Hewlett-Packard 185 C, H, N analyzer and agreed with theoretical values within (0.40%). Silica gel 60 (Merck 70–230 mesh) was used for column chromatography.

Preparation of Ecgonine Hydrochloride 2

Cocaine hydrochloride (**1**) (30.0 g, 99.6 mmol) was dissolved in 0.8N HCl (35% w/w, 150 mL) and heated at 105°C for 24 hrs. The resulting mixture was cooled to room temperature and left to stand for 30 minutes to 1 hr at 4°C. Precipitated benzoic acid was removed by washing with 200 mL of ether for three times. The water layer was collected, evaporated to dryness, then redissolved in CHCl₃ (500 mL) and stirred for 1 hr and evaporated under reduced pressure, and the resulting residue gave the corresponding compounds (**2**) with 100% yield (18.4 g). ¹H-NMR (CD₃OD): δ 4.35 (m, 1 H, H₃), 4.10 (d, 1 H, H₁), 3.88 (m, 1 H, H₅), 3.15 (dd, 1 H, H₄), 2.82 (s, 3 H, NCH₃), 2.36 (m, 2 H, H₆ and H₇), 2.10 (m, 3 H, H₄ and H₆ and H₇)

Preparation of (R)-(-)-Anhydroecgonine Methyl Ester 3

Ecgonine hydrochloride (**2**) (18.4 g, 99.5 mmol) was dissolved in 100 mL of POCl₃ and heated at 110°C to reflux for 3 hrs, the resulting mixture was cooled to room temperature and concentrated in vacuum under nitrogen gas, 200 mL of anhydrous methanol was added to sticky compounds and stirred until completely dissolved under ice water bath, then remove the water bath and stirred for

overnight. Water (150 mL) and NaOH were then added and the reaction mixture was extracted into CH₂Cl₂ (3 x 100 mL). The organic layers were combined, dried over Na₂SO₄, and concentrated in vacuum under nitrogen gas. The resulting mixture gave the corresponding compound (4) with 15.6 g, 86.1 mmol and 87% yield. ¹H-NMR (CD₃OD): δ 6.81 (m, 1 H, H₃), 3.98 (d, *J* = 5.6 Hz, 1 H, H₁), 3.94 (s, 3 H, OCH₃), 3.45 (m, 1 H, H₅), 2.83 (d, br, *J* = 19.8 Hz, 1 H, H₄), 2.54 (s, 3 H, NCH₃), 2.36 (m, 2 H, H₆ and H₇), 2.04 (m, 2 H, H₄ and H₇), 1.72 (m, 1 H, H₆).

Preparation of 2β-Carbomethoxy-3β-(4-Chlorophenyl)Tropine 4

Compound (3) (24.2 g, 133 mmol) dissolved in anhydrous CH₂Cl₂ (50 mL) was added dropwise of a stirred solution of the 1.0 M 4-chlorophenyl magnesium bromide (155 mL, 155.8 mmol) in solution of anhydrous CH₂Cl₂ (250 mL) at -40°C~-45°C under nitrogen gas for 3 hours. The mixture solution was cooled to -78°C, and a solution of CF₃COOH (12 mL, 155.8 mol) in anhydrous CH₂Cl₂ (10 mL) was added under nitrogen gas. The mixture was allowed to warm to room temperature and stirred for 30 min. H₂O (300 mL) was added, then pH was adjusted to 1 followed by acidifying with 12N HCl, it was neutralized by NaOH, after partition, water layers were combined, then was extracted into ether (3 x 200 mL). The ether layers were combined, dried over Na₂SO₄, and concentrated in vacuum under nitrogen gas. The resulting mixture was purified by chromatography to obtain colorless solid corresponding compounds (4) with 45.7% yield (17.8 g). ¹H-NMR(CDCl₃): δ 7.20 (AB, *J* = 8.8 Hz, 4 H, C₆, H₄), 3.56 (m, 1 H, H₁), 3.50 (s, 3 H, OCH₃), 3.35 (m, 1 H, H₅), 2.96 (td, 1 H, H₃), 2.87 (m, 1 H, H₂), 2.55 (td, 1 H, H₄), 2.22 (s, 3 H, NCH₃), 2.02-2.28 (m, 2 H, H₆ and H₇), 1.48-1.78 (m, 3 H, H₄, H₆ and H₇).

Preparation of 3β-(4-Chlorophenyl)-Nortropine-2β-Carboxylic Methyl Ester 5

To a stirred solution of the ecgonine hydrochloride (4) (2.0g, 6.8 mmol) in CH₂Cl₂ (100 mL) were added 1-chloroethyl-chloroformate (2.9g, 20.5 mmol). Stirring was prolonged at 50°C for 24 hours under nitrogen gas. The mixture was concentrated under reduced pressure followed by addition of 100 mL of CH₃OH and stirred at room temperature for 4 hours. The organic layer was separated, washed with water and saturated brine, and dried over Na₂SO₄. The filtrate was concentrated under reduced pressure to give the corresponding compound (5) with 80% yield

(1.6 g). LTQ-MS: *m/z* calculated for C₁₅H₁₈ClNO₂ [M+H]⁺ = 280.11, found 280.17.

Preparation of (E) 3-Iodoacrylic Acid 7

To propiolic acid (6) (6.8g, 97.3 mmol) in a double necked glass bottle under oil bath and nitrogen gas was added HI and stirred gently. The resulting mixture was stirred for 12 hours until precipitation of white crystal solid powder. The white crystal solid powder was filtered, washed with water and *n*-hexane, and was concentrated under reduced pressure to give the corresponding compounds (7) with 79% yield (15.4 g). ¹H NMR (300 MHz, CDCl₃) δ 8.09 (d, *J* = 14.8 Hz, 1H), 6.90 (d, *J* = 14.8 Hz, 1H).

Preparation of (E) Ethyl 3-Iodoprop-2-Enoic Acid 8

To a stirred solution of the (E) 3-Iodoacrylic acid (7) (5 g, 25.3 mmol) in absolute C₂H₅OH (30 mL) in a double necked glass bottle was added H₂SO₄ (1.7 mL, 30.3 mmol). Stirring was prolonged at stirring temperature of 80°C and reflux for 24 hours under nitrogen gas. Saturated NaHCO₃ was added dropwise to the orange resulting mixture until pH 7.4. The organic layer was separated, washed with EtOAc (20 mL) and saturated brine, and dried over MgSO₄, and solvent was distilled under reduced pressure. The resulting orange viscous residue was dissolved in ether (1 mL) and that was chromatographed on silica gel (Et₂O/*n*-hexane = 15:85, R_f = 0.62) to obtain the corresponding compound (8) with 40% yield (2.3 g). ¹H NMR (300 MHz, CDCl₃) δ 7.87 (d, *J* = 14.8 Hz, 1H), 6.87 (d, *J* = 14.9 Hz, 1H), 4.20 (q, *J* = 7.1 Hz, 2H), 1.29 (t, *J* = 7.1 Hz, 3H).

Preparation of (E) 3-Iodoprop-2-En-1-ol 9

To a stirred solution of the (E) Ethyl 3-Iodoprop-2-enoic acid (8) (2.3g, 10.3 mmol) in CH₂Cl₂ (40 mL) in a double necked glass bottle was added (i-Bu₂AlH)₂ (2.8g, 20.0 mmol). Stirring was prolonged at 600 rpm and temperature of -78°C for 45 minutes under nitrogen gas; the reaction mixture was allowed to warm to 0°C. Methanol (20 mL), 70% CH₃OH (20 mL) and water (20 mL) were sequentially added to the resulting solution and stirred at room temperature for 5 min. The white resulting mixture was extracted with 10% Potassium sodium tartrate (30 mL) and CH₂Cl₂ (10 mL) for three times. The organic layer was collected and extracted with 10% KNaC₄H₄O₆·4H₂O (30 mL) for three times, washed with saturated brine, and dried over Na₂SO₄. Solvent was distilled at 35°C under reduced pressure, the mixture residues was chromatographed on silica gel (60% Ether, R_f = 0.45) and

stained with 15% H₂SO₄ to obtain the corresponding pale compound (**9**) with 38% yield (710 mg). ¹H NMR (300 MHz, CDCl₃) δ 6.70 (dt, *J* = 14.5 Hz, 1H), 6.40 (dd, *J* = 14.5 Hz, 1H), 4.10 (dd, *J* = 5.0 Hz, 2H), 1.73 (s, 1H, -OH).

Preparation of (E)-3-Iodo-2-Propenyl-1-Methylbenzenesulfonate **10**

To a stirred solution of the (E) 3-iodoprop-2-en-1-ol (**9**) (710 mg, 3.9 mmol) in CH₂Cl₂ (10 mL) in a two necked glass bottle were added C₁₄H₁₄O₅S₂ (1.3 g, 3.9 mmol) and C₁₀H₂₁N (1.0 mL, 5.8 mmol). Stirring was prolonged at temperature of 50°C for 12 hours under nitrogen gas. The reaction mixture was concentrated under reduced pressure. The resulting residue was diluted with CH₂Cl₂ (3 mL) and extracted with *n*-hexane (20 mL), The organic layer was collected and chromatographed on silica gel (10% EtOAc, R_f = 0.45) and stained with KMnO₄(aq) to obtain the corresponding compound (**10**) with 81% yield (1.06 g). ¹H NMR (300 MHz, CDCl₃) δ 7.77 (dd, 2H), 7.35 (dd, 2H), 6.52 (m, 2H), 4.43 (dd, 2H), 2.45 (s, 3H).

Preparation of (E) N-3-Iodo-2-Propenyl-1-Yl-2β-Carbomethoxy-3β-(4-Chlorophenyl)nortropane **11**

To a stirred solution of the (E)-3-iodo-2-propenyl-1-methylbenzenesulfonate (**10**) (0.5 g, 1.6 mmol) in CH₂Cl₂ (10 mL) in a two necked glass bottle were added 3β-(4-chlorophenyl)-nortropane-2β-carboxylic methyl ester (**5**) (0.4 g, 1.6 mmol) and K₂CO₃ (0.2 g, 1.6 mmol) as a catalytic agent. Stirring was prolonged at temperature of 50°C for 20 hours under nitrogen gas, the appearance of the reaction mixture was changed from orange to turbidity and *p*-toluenesulfonic salt was salt out. The resulting mixture was chromatographed on silica gel (EtOAc/*n*-hexane = 1:4, R_f = 0.48) and stained with KMnO₄(aq) to obtain the corresponding compound (**11**) with 76% yield (534 mg). LTQ-MS: *m/z* calculated for C₁₈H₂₁ClNO₂ [M+H]⁺ = 446.04, found 446.13. ¹H NMR (300 MHz, CDCl₃) δ 7.24–7.16 (m, 4H), 6.52–6.45 (m, 1H), 6.20 (d, *J* = 14.4 Hz, 1H), 3.65 (s, 1H), 3.53 (s, 3H), 3.39 (s, 1H), 2.99–2.94 (m, *J* = 5.3 Hz, 1H), 2.85–2.75 (m, *J* = 6.5 Hz, 1H), 2.57 (td, *J* = 2.8 Hz, 1H), 2.15–1.91 (m, *J* = 4.5 Hz, 3H), 1.72–1.61 (m, 3H).

Preparation of (E) N-3-Iodo-2-Propenyl-1-Yl-2β-Carboxyl-3β-(4-Chlorophenyl)nortropane **12**

To a stirred solution of the (E) N-3-iodo-2-propenyl-1-yl-2β-carbomethoxy-3β-(4-chlorophenyl)nortropane (**11**) (115.7 mg, 0.3 mmol) in solution of 1,4-dioxane:H₂O = 1:1 (10 mL) at 110°C for 7 days. The reddish resulting mixture was

concentrated under reduced pressure and dried in vacuum to remove solvent. Then purified by silica gel (CH₂Cl₂:CH₃OH = 9:1) to obtain white solid corresponding compound (**12**) with 31% yield (35 mg) and chemical purity of 99%. LTQ-MS: *m/z* calculated for C₁₇H₁₉ClNO₂ [M+H]⁺ = 432.02, found 432.17. ¹H NMR (300 MHz, CDCl₃) δ 1.83–1.72 (m, 2H), 1.90 (m, *J* = 6.3 Hz, 2H), 2.17 (m, *J* = 9.3, 5.3 Hz, 2H), 2.36 (to, *J* = 13.5 Hz, 1H, CH, H-2), 2.67 (d, *J* = 6.0 Hz, 1H, CH, H-1), 3.10 (t, *J* = 5.6 Hz, 2H, CH₂, H-1'), 3.11 (q, *J* = 6.0 Hz, 1H, CH), 3.6 (s, 2H), 6.47 (d, *J* = 15.0 Hz, 1H, CH, H-3'), 6.62 (t, 1H, CH, H-2'), 7.14 (d, *J* = 9.0 Hz, 2H, H_{arom.}, meta), 7.27 (d, *J* = 9.0 Hz, 2H, H_{arom.}, ortho).

Preparation of 1,4-Di-Tert-Butyl 2,2'-(7-(2-Ethoxyl)-1,4,7-Triazonan-1,4-Diyl) Diacetate **16**

To a stirred solution of the NOTA(t-Bu)₂ (**14**) (200 mg, 0.6 mmol) and 2-Bromoethanol (**15**) (70 mg, 0.6 mmol) in CH₂Cl₂ (10 mL) were added Et₃N (41.8 ul, 0.3 mmol) as a catalytic agent. Stirring was prolonged at temperature of 50°C for 12 hours, the resulting mixture was purified by MPLC (RP-18 column, 250×4.1 mm, flow rate 1 mL/min, gradient program of 10% CH₃OH to 90% CH₃OH in 15 minutes). The residue was concentrated under reduced pressure to give the 96.4 mg yellow pale oil corresponding compounds (**16**) with 85% yield (96.4 mg). LTQ-MS: *m/z* calculated for C₂₀H₃₉N₃O₅ [M+H]⁺ = 402.30, found 402.39.

Preparation of 2,2'-(7-(2-Ethoxyl)-1,4,7-Triazonan-1,4-Diyl)Diactic Acid **17**

To a stirred solution of the 1,4-di-tert-butyl 2,2'-(7-(2-ethoxyl)-1,4,7-triazonan-1,4-diyl)diacetate (**16**) (96.4 mg, 0.2 mmol) in solution of CH₂Cl₂:TFA = 1:1 (10 mL). Stirring was prolonged at room temperature for 4 hours, ice-cooled ether was added dropwise to stirred solution, water (5 mL) was added and evaporated under reduced pressure, and the white solid corresponding compound (**17**) was obtained in 99% yield (69 mg). LTQ-MS: *m/z* calculated for C₁₂H₂₃N₃O₅ [M+H]⁺ = 290.17, found 290.4.

Preparation of N-t-Boc-(O-*p*-Tosyl)-2-Aminoethanol **18**

To a stirred solution of the N-t-Boc-ethanolamine (1 g, 6.2 mmol) in CH₂Cl₂ (10 mL) and Et₃N (1.9 mL, 13.6 mmol) above ice bath, *p*-TsCl (1.4 g, 7.4 mmol) was dissolved in CH₂Cl₂ (10 mL) that was added dropwise to stirred solution of the N-t-Boc-ethanolamine. Stirring was prolonged at room temperature for 48 hours under nitrogen gas, the resulting mixture was extracted with 10% NH₄Cl (5 mL) twice and washed with saturated brine (10 mL) and dried over MgSO₄, and organic layer was concentrated under

reduced pressure to provide the white solid corresponding compound (**18**) with 84% yield (1.6 g). ¹H NMR (300 MHz, cdcl₃) δ 7.79 (d, *J* = 8.3 Hz, 1H), 7.39–7.33 (d, 1H), 4.10–4.03 (t, 1H), 3.38 (s, 1H), 2.45 (s, 2H), 1.41 (s, 5H).

Preparation of 1,4-Di-Tert-Butyl 2,2'-(7-(2-Aminoethyl)-1,4,7-Triazonan-1,4-Diyl)Diacetate **19**

To a stirred solution of the NOTA(t-Bu)₂ (**14**) (200 mg, 0.6 mmol) and *N*-t-Boc-(*O*-*p*-tosyl)-2-aminoethanol (**18**) (264.6 mg, 0.8 mmol) in CH₂Cl₂ (5 mL) were added Et₃N (0.1 mL, 0.7 mmol) as a catalytic agent. Stirring was prolonged at room temperature for 12 hours, the resulting mixture was purified by MPLC (PRP-1 column, 250×4.1 mm, flow rate 1 mL/min, gradient program of 10% CH₃OH to 90% CH₃OH in 15 minutes). The residue of LTQ-M responded data were collected and concentrated under reduced pressure to afford the pale oil corresponding compounds (**19**) with 52% yield (148 mg). LTQ-MS: *m/z* calculated for C₂₅H₄₈N₄O₆ [M+H]⁺ = 501.37, found 501.47.

Preparation of 2,2'-(7-(2-Aminoethyl)-1,4,7-Triazonan-1,4-Diyl)Diacetic Acid **20**

To a stirred solution of the 1,4-di-tert-butyl 2,2'-(7-(2-aminoethyl)-1,4,7-triazonan-1,4-diyl)diacetate (**19**) (148 mg, 0.3 mmol) in solution of CH₂Cl₂:TFA = 1:1 (10 mL). Stirring was prolonged at room temperature for 4 hours, ice-cooled ether was added dropwise to stirred solution, H₂O (5 mL) was added to dilute, and solvent was distilled under reduced pressure, the resulting residue (**20**) was obtained in 93% yield (80 mg). LTQ-MS: *m/z* calculated for C₁₂H₂₄N₄O₄ [M+H]⁺ = 289.19, found 289.23.

Preparation of 8-[(2*E*)-3-Iodo-2-Propenyl]-2β-[(2-(4,7-Bis(2-Ethylcarboxyl) -1,4,7-Triazonan-1-Yl) Ethyl)Oxy]Carboxyl-3β-(*p*-Chlorophenyl) Nortropane (IPCET-NOTA) **21**

To a stirred solution of the (*E*) *N*-3-iodo-2-propen-1-yl-2β-carboxyl-3β-(4-chlorophenyl)nortropane (**12**) (20.5 mg, 0.04 mmol) in anhydrous CH₂Cl₂ (1 mL) in reaction vial under nitrogen gas was added oxalyl chloride (12.0 mg, 0.09 mmol) immediately. Stirring was prolonged at room temperature for 3 hours. The resulting mixture (**13**) was concentrated under reduced pressure and dried in vacuum for 6 hours to remove oxalyl chloride. 2,2'-(7-(2-ethoxy)-1,4,7-triazonan-1,4-diyl)diacetic acid (**17**) (83.3 mg, 0.3 mmol) was dissolved in anhydrous DMF and added TEA (199 μL, 1.4 mmol), the solution was added to the reaction vial under reduced pressure for 2 hours. The resulting mixture was purified by HPLC (PRP-1 column, 250×4.1 mm,

flow rate 1 mL/min, gradient program of 10% CH₃OH to 90% CH₃OH in 15 minutes) to obtain the white solid corresponding compounds (**21**) with less than 2% yield (0.2 mg) and less than 5% of chemical purity. LTQ-MS: *m/z* calculated for C₂₉H₄₁ClIN₄O₆ [M+H]⁺ = 703.18, found 703.08.

Preparation of 8-[(2*E*)-3-Iodo-2-Propenyl]-2β-[(2-(4,7-Bis(2-Ethylcarboxyl) -1,4,7-Triazonan-1-Yl) Ethyl)Carboxamido-3β-(*p*-Chlorophenyl)Nortropane (IPCAT-NOTA) **22**

To a stirred solution of the (*E*) *N*-3-iodo-2-propen-1-yl-2β-carboxyl-3β-(4-chlorophenyl) nortropane (**12**) (17.6 mg, 0.04 mmol) in anhydrous CH₂Cl₂ (1 mL) in reaction vial under nitrogen gas was added oxalyl chloride (10.4 mg, 0.08 mmol) immediately. Stirring was prolonged at room temperature for 3 hours. The resulting mixture (**13**) was concentrated under reduced pressure and dried in vacuum for 6 hours to remove oxalyl chloride. 2,2'-(7-(2-aminoethyl)-1,4,7-triazonan-1,4-diyl)diacetic acid (**20**) (23.5 mg, 0.08 mmol) was dissolved in anhydrous DMF and added TEA (22.7 μL, 0.16 mmol) as a catalytic agent, the solution was added to the reaction vial under reduced pressure for 2 hours. The resulting mixture was purified by HPLC (PRP-1 column, 250×4.1 mm, flow rate 1 mL/min, gradient program of 10% CH₃OH to 90% CH₃OH in 15 minutes) to obtain the white solid corresponding compounds (**22**) with 2% yield (0.6 mg). LTQ-MS: *m/z* calculated for C₂₉H₄₁ClIN₅O₅ [M+H]⁺ = 702.19, found 702.15.

Synthesis of [⁶⁸Ga]IPCET-NOTA **23**

For radiolabeling, 0.1 mL [⁶⁸Ga]GaCl₃ (~74 MBq) and 10 μg (14.2 nmol) of IPCAT-NOTA **21** were added to 30 μL 1M HEPES buffer. The final pH of the reaction mixture was 4.1 ~ 4.3, which incubated at room temperature for 15 minutes. For quality control, the product was analyzed by radio-TLC, silica gel plate TLC-SG (1.5 × 6 cm) with 0.1 M EDTA as the mobile phase was used. In this system, radiolabeled ligand remain at the origin (R_f = 0–0.1) while free gallium-68 migrates with the solvent front (R_f = 0.8–1).

Synthesis of [⁶⁸Ga]IPCAT-NOTA **24**

For radiolabeling, 0.1 mL [⁶⁸Ga]GaCl₃ (~74 MBq) and 10 μg (14.2 nmol) of IPCAT-NOTA **22** were added to 30 μL 1M HEPES buffer. The final pH of the reaction mixture was 4.1 ~ 4.3, which incubated at room temperature for 15 minutes. For quality control, the product was analyzed by radio-TLC, silica gel plate TLC-SG (1.5 × 6 cm) with 0.1 M EDTA as the mobile phase was used. In this system, radiolabeled

ligand remained at the origin ($R_f = 0-0.1$) while free gallium-68 migrates with the solvent front ($R_f = 0.8-1$).

Biological

Adult male SD rats (BioLASCO Taiwan Co., Taipei, Taiwan), approximately six weeks old and 193–224 g at the beginning of the experiments were maintained under an artificial 12-h light/dark cycle (light on from 8:00 a.m. to 8:00 p.m.) at a constant temperature, and maintained at $21 \pm 2^\circ\text{C}$ with $50 \pm 20\%$ relative humidity. Food and water were freely available, and the animals were acclimated for >7 days before use. Experiments were performed between 8:00 a.m. and 2:00 p.m. All the animal experiments were conducted in accordance with “A Guidebook for the care and use of laboratory animals (3rd edition, 2010)”. The animal experiment application was filed to the Ethical Animal Use Committee of Institute of Nuclear Energy Research (INER) and approved in 2015 with the IACUC number of 104132. The application indicated the personnel participated in animal experiments (including the experience for performing animal experiments, the education and training procedures), the number of animals required, the methods and procedures of animal experiments (including methods and procedures for reducing animal suffering and humane treatment process), animal disposal methods after the end of the experiment, etc. The experience, education, and training for the personnel participated in animal experiments also indicated on the application form. All the experiments were carried out after approval by the Laboratory Animal Care and Use Committee of INER.

Determination of Partition Coefficients (LogP)

The partition coefficients (log P) of [^{68}Ga]IPCAT-NOTA **24** was determined by adding 3.7 MBq of labeled complex to a solution containing 2.5 mL of 1-octanol and 2.5 mL of phosphate buffer saline (PBS; pH 7.4). The resulting solutions were then vigorously vortexed for 10 minutes at room temperature and centrifuged for 2 minutes at 1000 rpm. Octanol (0.1 mL) was removed and back extracted with 0.5 mL of 1-octanol and 2.5 mL of PBS, repeat steps sixfold. Finally, octanol (2 mL) was removed and counted. Aliquots samples were taken from each phase and assayed the radioactivity in a gamma counter (1470 WIZARD Gamma Counter, Wallac, Finland). The partition coefficient was calculated as a ratio of counts in the octanol fraction to counts in the water fraction per extraction. The experiment was performed in triplicate.

In vitro Serum Stability

Serum preparation: Health SD rat was deeply anesthetized with isoflurane gas (3% isoflurane in 50% oxygen, 1 mL/min). 1 mL whole blood of health SD rat was withdrawn through tail vein at room temperature and centrifuged at 3000 rpm/min for 10 minutes to achieve a prepared serum for stability test.

Stability in serum. The stability was studied by incubation of 3.7MBq of [^{68}Ga]IPCAT-NOTA **24** in 200uL of prepared serum at 37°C . At different time points (5, 10, 30, and 60 minutes), each sample was treated with 1 mL of acetonitrile for precipitating the serum proteins. After mixing and centrifuging for 2 minutes at 5000 rpm, the radiochemical purity of [^{68}Ga]IPCAT-NOTA **24** was determined using radio-TLC methods. Radio-TLC was performed on a silica gel plate TLC-SG (1.5×6 cm), using 0.1M EDTA as the developing agent.

In vitro Autoradiography (Binding and Competitive Assay)

The binding and competitive studies were carried out in 20 μm thick cryostat-cut sagittal section slices of brain tissue of SD rat. After unfreezing of the section slices, the slices were immediately rinse with water for recovery. 500 μCi of [^{68}Ga]IPCAT-NOTA **24** (binding assay) was incubated with 1:1, 1:100 and 1:1000 ratio of precursor (competitive assay) in 100% $\text{C}_2\text{H}_5\text{OH}$ solution, respectively. Incubation of reacted slices at room temperature for 1 h with gentle and constant shaking and then transferred to a glass tank of 40% $\text{C}_2\text{H}_5\text{OH}$ for 1 minute as well as water for 1 minute, repeat steps twice. The slices were dried on a warm dryer and placing in the image of the Imaging plate cassette (2040, Fuji Photo Film Co., Tokyo, Japan) for automatic exposure for at least 7 days. The image was counted and analyzed by FLA-5000 (Fuji Photo Film Co., Tokyo, Japan) and software Science Lab V4.0 (Fuji Photo Film Co., Tokyo, Japan). The specific binding ratio (SBR%) can be calculated by the formula as follows.

$$\text{SBR}\% = \frac{\text{activity of striatum} - \text{activity of cerebellum}}{\text{activity of cerebellum}} \times 100\%$$

Ex vitro Autoradiography

Health SD rat was injected with 55.5 MBq/0.1 mL of [^{68}Ga]IPCAT-NOTA **23** through lateral tail veins. The rat was sacrificed by CO_2 euthanasia at 60 minutes and 120 minutes postinjection, and immediately dipped into isopentane (Nacalai Tesque Inc., Japan) which will be pre-chilled with liquid nitrogen. The whole brain was frozen

for 1–2 minutes and placed on a cryostat holder (7 x 5 cm) and embedded with 4% carboxymethylcellulose (CMC). The specimens were placed in a cryostat (Bright Instrument Company Ltd., UK) and sliced (thickness 20 μ m) at a constant temperature of -40°C . The sections were placed on an imaging plate cassette (2040, Fuji Photo Film Co., Tokyo, Japan) for automatic exposure for at least 7 days. The image was counted and analyzed by FLA-5000 (Fuji Photo Film Co., Tokyo, Japan) and software Science Lab V4.0 (Fuji Photo Film Co., Tokyo, Japan).

In vitro Metabolite Assay

Ault male Health SD rat was injected with 55.5 MBq/0.1 mL of [^{68}Ga]IPCAT-NOTA **24** through lateral tail veins and distributed for 5, 10, 30 minutes, Health SD rat was deeply anesthetized with isoflurane gas (3% isoflurane in 50% oxygen, 1 mL/min). 1 mL whole blood of rat was withdrawn through tail vein at room temperature and centrifuged at 3000 rpm for 10 min to achieve supernatant. The radiochemical purity of [^{68}Ga]IPCAT-NOTA **24** was determined using radio-TLC methods. Radio-TLC was performed on a silica gel plate TLC-SG (1.5 x 6 cm), using 0.1 M EDTA as the developing agent.

In vivo NanoPET/CT Image

Health SD rat was intravenously injected with 37 MBq/0.1 mL of [^{68}Ga]IPCAT-NOTA **24** through lateral tail veins and anesthetized with isoflurane gas (3% isoflurane in 50% oxygen, 1 mL/min). The imaging of [^{68}Ga]IPCAT-NOTA **24** was acquired for 60 minutes using nanoPET/CT (BioScan, Inc., Washington, DC, USA) with dynamic image and semi-quantification was processed by PMOD software (PMOD Technologies Ltd., Zürich, Switzerland). We set up a PMOD template for brain including striatum and cerebellum, respectively. Cerebellum served as the reference region, and region of interest (ROI) was calculated from the average radioactivity with the following equation: (target - reference)/reference.

In vivo Regional Brain Distribution

Regional brain distribution in SD rats was measured after an i.v. injection of the 37 MBq/0.1 mL of [^{68}Ga]IPCAT-NOTA **24**. Samples from different brain regions (cortex, striatum, hippocampus, and cerebellum) were dissected, weighed and counted (WIZARD2 2480, PerkinElmer Instruments Inc.). The percentage dose/g of each sample was calculated by comparing sample counts with the counts of the diluted initial dose described above. The % ID/g of specific uptake in each region was obtained by

dividing the difference between the biodistribution of striatum and cerebellum image data.


Results and Discussion

Chemical Preparation


Starting from cocaine, compound **12** was synthesized (Scheme 1) through the substitution reaction of compound **10** (Scheme 2) at the N-8 position. Compounds **17** and **20** were prepared (Scheme 3) from ethylene glycol and diethylenetriamine as starting precursors, and then compound **13** reacted with compound **17** and **20** through substitution reaction to produce IPCET-NOTA **21** and IPCET-NOTA **22** with <5% yield, and only IPCAT-NOTA **22** had chemical purity of >99%. The yields of IPCAT-NOTA **21** and IPCAT-NOTA **22** were <5% because of the steric hindrance of NOTA-OH and NOTA-NH₂. The structures of 2,2'-(7-(2-ethoxyl)-1,4,7-triazonan-1,4-diyl)diacetic acid **21** and 2,2'-(7-(2-aminoethyl)-1,4,7-triazonan-1,4-diyl)diacetic acid **22** were bulky to react with the C-2 position of tropane derivatives.

Radiochemistry and Serum Stability

First, IPCET-NOTA **21** and IPCAT-NOTA **22** were chelated with [^{68}Ga]GaCl₃ to produce [^{68}Ga]IP CET-NOTA **23** and [^{68}Ga]IPCAT-NOTA **24** in HEPES buffer at pH 4.1–4.3 for 15 minutes (Scheme 4). The specific activity of labeled ligand was poor if the amount of NOTA was <10 μ g (data not shown). Both [^{68}Ga]IP CET-NOTA **23** and [^{68}Ga]IPCAT-NOTA **24** were obtained with a high radiochemical yield of $\geq 90\%$ and specific activity of 4.25 MBq/nmol (Figure 1). Regarding biological experiments, [^{68}Ga]IPCAT-NOTA **24** was selected as the follow-up biological test item because the precursor IPCAT-NOTA **22** had >99% chemical purity. In general, Ga(III) could form stable complexes with 4-, 5-, or 6-coordinate ligands, with 6-coordinate ligands being the most stable.¹⁸ NOTA was accepted as the “gold standard” chelator for gallium-67 ([^{67}Ga]) or gallium-68 ([^{68}Ga]), and Ga-NOTA has a high formulation constant and in vivo kinetic stability; although NOTA was used to conjugate with the molecule, one of the carboxyl groups becomes unavailable for the coordination,¹³ but it remains stable. Moreover, 2 MBq of [^{68}Ga]IPCAT-NOTA **24** was incubated at 37°C with the serum isolated from healthy Sprague Dawley (SD) rat (Table 1); the radiochemical purity (RCP%) values of [^{68}Ga]IPCAT-NOTA **24** were 90.69%, 86.09%, 88.64%, 90.39%, and 89.12% at 0, 5, 10, 30, and 60 minutes, respectively. Our stability result



Scheme 1 Synthesis of IPCET-NOTA **21** and IPCAT-NOTA **22**.




Scheme 2 Synthesis of (E)-3-iodo-2-propenyl-1-methylbenzenesulfonate **10**.


shows that intact [^{68}Ga]IPCAT-NOTA **24** is >85% up to 1 hour under physiological conditions, and the precursor IPCAT-NOTA **22** of [^{68}Ga]IPCAT-NOTA **24** could stably chelate with ^{68}Ga even when it has 5-coordinate ligands.

Partition Coefficient (LogP)

The octanol-water partition coefficient (LogP) of [^{68}Ga]IPCAT-NOTA **24** was determined to be 0.88 ± 0.30 . In addition, the cLogP values of precursors IPCAT-NOTA **22**, IPCET-NOTA **21**,



Scheme 3 Synthesis of 2,2'-(7-(2-ethoxy)-1,4,7-triazonan-1,4-diyl)diacetic acid **17** and 2,2'-(7-(2-aminoethyl)-1,4,7-triazonan-1,4-diyl) diacetic acid **20**.



Scheme 4 Preparation of radiolabeled probe of [⁶⁸Ga]IPCAT-NOTA **23** and [⁶⁸Ga]IPCET-NOTA **24** (X = O, for IPCET and X = N, for IPCAT).




Figure 1 Radiochemical purity (RCP) analysis of [⁶⁸Ga]IPCET-NOTA **23** (I) and [⁶⁸Ga]IPCAT-NOTA **24** (II).

Table 1 In vitro Serum Stability of [^{68}Ga]IPCAT-NOTA **24** the Stability of [^{68}Ga] IPCAT-NOTA **24** Were 90.69%, 86.09%, 88.64%, 90.39% and 89.12% at 0,5,10,30, and 60 Minutes, Respectively

Time (Min)	Radiochemical Purity (RCP, %)
0	96.69
5	86.09
10	88.64
30	90.39
60	89.12

and TRODAT-1 were estimated as 2.39, 3.07, and 3.34, respectively, by using ChemDraw (data not shown). An ideal radiotracer for brain imaging should be relatively small, neutral, and lipophilic to cross the intact blood–brain barrier (BBB). According to Dischino et al,¹⁹ an ideal radiopharmaceutical design to pass the BBB should have a LogP value of 0.9–2.5. Our result shows that the LogP value of [^{68}Ga]IPCAT-NOTA **24** was 0.7, which is on

the borderline of the range suggested by Dischino; it was assumed that it has partial ability to cross the BBB. However, [^{68}Ga]IPCAT-NOTA **24** may fail to reach the target due to the slightly positively charged ^{68}Ga /chelator-complex, which cannot pass the intact BBB, which is consistent with the result from the estimation of quantitative structure–activity relationship computer models of Discovery Studio (data not shown).

Autoradiography and Competition Assay

In vitro Autoradiography

The specific binding ratio (SBR%) of [^{68}Ga]IPCAT-NOTA **24** was 18% in healthy rats (Figure 2). In a competition study, SBR% of [^{68}Ga]IPCAT-NOTA **24** was significantly inhibited (up to 85% and 100%) through coincubation with a nonradioactive precursor at 100- and 1000-fold concentration in the DAT-rich regions of the brain (striatum; Figure 3 and Table 2). Furthermore, we analyzed and




Figure 2 In Vitro Autoradiography of [^{68}Ga]IPCAT-NOTA **24** (A and B) and [$^{99\text{m}}\text{Tc}$]TRODAT-1 (C and D) in health SD rat. Specific binding of [^{68}Ga]IPCAT-NOTA **24** and [$^{99\text{m}}\text{Tc}$]TRODAT-1 in striatum (solid arrow) and cerebellum (hollow arrow).




Figure 3 In Vitro Autoradiography (Competitive assay) of [^{68}Ga]IPCAT-NOTA **24** with different fold of non-radioactive precursor in the DAT rich regions (striatum) of brain. The SBR (%) of [^{68}Ga]IPCAT-NOTA **24** were (A) 1:1 ratio, (B) 1:100 ratio and (C) 1:1000 ratio, respectively (solid arrow).

Table 2 In vitro Autoradiography (Include Competition Assay) Analysis

PSL	1:1	1:100	1:1000
Striatum	538.62±49.77	418.92±81.68	567.55±60.80
Cerebellum	541.07±63.58	552.25±15.23	601.34±37.17
Specific Binding Ratio (%) (SBR%)	15.76±3.74	6.49±4.46	-11.67±4.65

Notes: Specific Binding Ratio (%) (SBR%) = $(s-c)/c \times 100\%$. s: striatum average count value (P-B)/mm². c: cerebellum average count value (P-B)/mm². P: Photostimulated luminescence (PSL) value. B: Background value.

compared the amount of DAT in cerebellum, cortex, and striatum of younger (5-week-old) and older (21-week-old) healthy SD rats by using ELISA. The results showed that the DAT concentration in older rats was more than that in younger rats (data not shown). In addition, the binding affinity of [⁶⁸Ga]IPCAT-NOTA **24** exhibits less potency than that of [^{99m}Tc]TRODAT-1. However, the ST to CB ratio was low when a higher carrier amount was added, which indicates that the excess free ligand would result in the specific binding of [⁶⁸Ga]IPCAT-NOTA **24**.

Ex vivo Autoradiography

The SBR% values of [⁶⁸Ga]IPCAT-NOTA **24** were estimated through intravenous injection of 30 MBq/100μL of [⁶⁸Ga]IPCAT-NOTA **24** in healthy SD rats followed by their sacrifice to observe brain coronal sections 60 and 120 minutes after injection. Our result revealed that the SBR% of [⁶⁸Ga]IPCAT-NOTA **24** in healthy SD rats was $15.8 \pm 6.7\%$ and at 60 and 120 minutes after [^{99m}Tc]TRODAT-1 injection, they were $82.3 \pm 0.7\%$ and $214.7 \pm 1.6\%$ (data not shown), respectively (Figure 4). Compared with [^{99m}Tc]




Figure 4 Ex Vitro Autoradiography of [⁶⁸Ga]IPCAT-NOTA **24**. The IP and Digital imaging of striatum and cerebellum of [⁶⁸Ga]IPCAT-NOTA **24** at 60 minutes (A) and 120 minutes (B) post-injection, respectively. (C) The SBR (%) of [⁶⁸Ga]IPCAT-NOTA **24** after 60 minutes and 120 minutes distribution.

TRODAT-1, [^{68}Ga]IPCAT-NOTA **24** exhibited less binding affinity to DAT. Notably, the stability of [^{68}Ga]IPCAT-NOTA **24** during the ex vivo procedure remains unknown. Furthermore, the ^{68}Ga complexing moiety (ie, NOTA) is inherently bulky and hydrophilic, which most likely does not pass the BBB and leads to less binding affinity to DAT. Moreover, the limitation of this study is that ^{68}Ga has a half-life of 68 minutes, which requires rapid use of the tracer after its generation and high radiolabel-specific activity of [^{68}Ga]IPCAT-NOTA **24** to achieve high imaging quality.

NanoPET/CT Image and Regional Brain Distribution

The NanoPET/CT imaging data of SD rats showed that the SBR% values of the striatum of [^{68}Ga]IPCAT-NOTA **24** were 6%, 25%, and 62% at 5–15, 30–40, and 60–70 minutes, respectively (Figure 5). Furthermore, the striatum/cerebellum ratios of [^{68}Ga]IPCAT-NOTA **24** were 1.05, 1.25, and 1.62 at 5–15, 30–40, and 60–70 minutes, respectively. For other radiotracers, the striatum/cerebellum ratios at 60 minutes after injection of [$^{99\text{m}}\text{Tc}$]TRODAT-1³ and [^{18}F]FECNT²⁰ were 2.8 and 1.52, respectively. The striatal uptake at 45 min postinjection of [^{18}F]LBT-999 and [^{11}C]LBT-999 were 2.5 ± 0.4 and $4.2 \pm 0.4\%$ ID/g, respectively.²¹

In a head-to-head comparison of dopamine transporter SPECT radioligands [^{123}I]FP-CIT and [^{123}I]PE2I in health subjects, both of them had approximately about 3 folds ratios.²² At 60 minutes after injection of [^{68}Ga]IPCAT-NOTA **24**, this ratio reached 1.62, the result was similar with [^{18}F]FECNT but significantly lower than other radiotracer. This indicates that [^{68}Ga]IPCAT-NOTA **24** could still strongly bind to DAT. However, most of [^{68}Ga]IPCAT-NOTA **24** were in the outer nonspecific binding regions due to low lipophilicity and tendency to be washed out quickly from the brain, with appearance in the liver and bladder at 5–15 and 30–40 minutes (Figure 6). Moreover, compared with the uptake data of [$^{99\text{m}}\text{Tc}$]TRODAT-1 of 0.4% at 2 minutes and 0.12% at 1 hour after injection,³ the overall brain uptake was calculated from all brain regions (cortex, striatum, hippocampus, and cerebellum). The results showed that the overall brain uptake was 0.07% ID/g at 30 hours after injection due to the less penetration.

Metabolite Assay

The in vitro metabolite assay of [^{68}Ga]IPCAT-NOTA **24** showed that the RCP% values at 0, 5, 10, and 30 minutes were 92.58%, 84.03%, 79.01%, and 67.65%, respectively (Table 3). Thus, [^{68}Ga]IPCAT-NOTA **24** was




Figure 5 Coronal views of NanoPET/CT images of SD rats at (A) 5–15 min, (B) 30–40 min and (C) 60–70 min after intravenous injection of [^{68}Ga]IPCAT-NOTA **24**. Quantified uptake of [^{68}Ga]IPCAT-NOTA **24** in striatum and cerebellum (lower panel).




Figure 6 Sagittal views of NanoPET/CT whole body images of SD rats at (A) 5–15 min, (B) 30–40 min and (C) 60–70 min after intravenous injection of [^{68}Ga]IPCAT-NOTA 24. The radiotracer was fastly washed-out from brain and appeared in the liver (solid arrow) and bladder (dotted solid arrow) at 5–15 minutes and in the kidney (dotted hollow arrow) at 30–40 minutes, respectively.

unstable in blood for a long duration. One possible reason is the most prominent gallium interaction in plasma: gallium transchelation to serum proteins, such

Table 3 In vivo Metabolite Study of [^{68}Ga]IPCAT-NOTA 24 Showing the Radiochemical Purity (RCP%) at 0, 5, 10, and 30 Minutes Were 92.58%, 84.03%, 79.01%, and 67.65%, Respectively

Time (Min)	Radiochemical Purity (RCP, %)
0	92.58
5	84.03
10	79.01
30	67.65

as iron transport protein transferrin (a monomeric glycoprotein). Only one-third of the iron-binding sites of transferrin was typically occupied, leaving the other free binding sites to coordinate with gallium. Thus, free [^{68}Ga] would easily detach from NOTA and conjugate with transferrin. We concluded that free gallium in serum is primarily bound to transferrin in equilibrium with gallate species [$\text{Ga}(\text{OH})_4$].²³ The prolonged circulating time allows increased radioactive metabolite formation, and most of the less lipophilic metabolites observed at 30 minutes would form [^{68}Ga]IPCAT-NOTA 24, which could not pass through the BBB. This study's limitation is the unknown stability and rapid in vivo kinetics of

[⁶⁸Ga]IPCAT-NOTA **24** during the in vivo metabolite procedure. Future studies evaluating radiotracer stability under various pH conditions and analyzing the amount of labeled transferrin and metabolites are warranted.

Conclusion

Precursor IPCAT-NOTA **22** was efficaciously labeled with ⁶⁸Ga. The [⁶⁸Ga] complex was easily chelated with a RCP % of >95%. Because of the presence of LogP and carboxyl group of NOTA, [⁶⁸Ga]IPCAT-NOTA **24** may not be a potential imaging agent for DAT. However, the in vitro binding affinity of [⁶⁸Ga]IPCAT-NOTA **24** is noteworthy because of its structural features, which leads to the development of PET probe in conjugate/pendent approach for DAT imaging. To evaluate the relationship between [⁶⁸Ga]IPCAT-NOTA **24** uptake and transporter localization, a different chelator must be used or direct intracranial injection must be administered.

Acknowledgments

Authors would like to thank Cheng-Li, Chou Ph.D. for providing the LogP estimation of QSAR computer models by Discovery Studio software and the financial support of MOST (NSC 104-3111-Y-042A-065).

Disclosure

Shiou-Shiow Farn and Kang-Wei Chang are co-first authors. The authors declare that they have no conflicts of interest.

References

- Goodman MM, Keil R, Shoup TM, et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. *J Nucl Med.* 1997;38(1):119–126.
- Koivula T, Marjamaki P, Haaparanta M, et al. Ex vivo evaluation of N-(3-[18F]fluoropropyl)-2 beta-carbomethoxy-3 beta-(4-fluorophenyl) nortropane in rats. *Nucl Med Biol.* 2008;35(2):177–183. doi:10.1016/j.nucmedbio.2007.09.006
- Meegalla SK, Plossl K, Kung MP, et al. Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. *J Med Chem.* 1998;41(4):428–436. doi:10.1021/jm970742b
- Abi-Dargham A, Kegeles LS, Zea-Ponce Y, et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. *Biol Psychiatry.* 2004;55(10):1001–1006. doi:10.1016/j.biopsych.2004.01.018
- Abbasi Gharibkandi N, Hosseinimehr SJ. Radiotracers for imaging of Parkinson's disease. *Eur J Med Chem.* 2019;166:75–89. doi:10.1016/j.ejmech.2019.01.029
- Ma KH, Huang WS, Chen CH, et al. Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned Formosan rock monkeys. *Nucl Med Biol.* 2002;29(5):561–567. doi:10.1016/S0969-8051(02)00303-7
- Kung HF. Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent. *Nucl Med Biol.* 2001;28(5):505–508. doi:10.1016/S0969-8051(01)00220-7
- Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. *Eur J Nucl Med.* 1996;23(11):1527–1530. doi:10.1007/BF01254479
- Kung HF, Meegalla S, Kung MP, Plössl K. Development of 99mTc-labelled complexes for imaging dopamine transporters in the brain. *Transit Met Chem.* 1998;23(4):531–536. doi:10.1023/A:1006921811871
- Johannsen B, Pietzsch HJ. Development of technetium-99m-based CNS receptor ligands: have there been any advances? *Eur J Nucl Med Mol Imaging.* 2002;29(2):263–275. doi:10.1007/s002590100652
- Stepanov V, Krasikova R, Raus L, Loog O, Hiltunen J, Halldina C. An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters. *J Label Compd Radiopharm.* 2012;55(6):206–210. doi:10.1002/jlcr.2927
- Kilian K. 68Ga-DOTA and analogs: current status and future perspectives. *Rep Pract Oncol Radiother.* 2014;19(Suppl):S13–S21. doi:10.1016/j.rpor.2014.04.016
- Velikyan I. Continued rapid growth in (68) Ga applications: update 2013 to June 2014. *J Labelled Comp Radiopharm.* 2015;58(3):99–121.
- Kaemmerer D, Peter L, Lupp A, et al. Molecular imaging with (6)(8) Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2011;38(9):1659–1668. doi:10.1007/s00259-011-1846-5
- Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. *Cancer Imaging.* 2020;20(1):10. doi:10.1186/s40644-020-0290-9
- Ostapchenko VG, Snir J, Suchy M. Detection of active caspase-3 in mouse models of stroke and alzheimer's disease with a novel dual positron emission tomography/fluorescent tracer [68Ga]Ga-TC3-OGDOTA. *Contrast Media Mol Imaging.* 2019;2019:17. doi:10.1155/2019/6403274
- Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. *Chem Soc Rev.* 2014;43(1):260–290.
- Cutler CS, Giron MC, Reichert DE, et al. Evaluation of gallium-68 tris(2-mercaptobenzyl)amine: a complex with brain and myocardial uptake. *Nucl Med Biol.* 1999;26(3):305–316. doi:10.1016/S0969-8051(98)00108-5
- Dishino DD, Welch MJ, Kilbourn MR, Raichle ME. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. *J Nucl Med.* 1983;24(11):1030–1038.
- Zoghbi SS, Shetty HU, Ichise M, et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. *J Nucl Med.* 2006;47(3):520–527.
- Saba W, Peyronneau MA, Dolle F, Goutal S, Bottlaender M, Valette H. Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies. *Nucl Med Biol.* 2012;39(2):227–233. doi:10.1016/j.nucmedbio.2011.08.003
- Ziebell M, Holm-Hansen S, Thomsen G, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. *J Nucl Med.* 2010;51(12):1885–1891. doi:10.2967/jnumed.110.078337
- Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. *Biochemistry.* 1983;22(2):292–299. doi:10.1021/bi00271a010

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>